Related Experiment Video

Updated: Jul 13, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The effect of angiotensin receptor blockers for preventing atrial fibrillation

Kristian Wachtell1, Richard B Devereux, And Paulette A Lyle

  • 1Department of Cardiology B2142, Rigshospitalet, The Heart Center, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. kristian@wachtell.net

Current Hypertension Reports
|August 10, 2007
PubMed

Insights

Atrial fibrillation, a common heart rhythm disorder, poses a significant health burden. Angiotensin receptor blockers show promise in preventing this condition by targeting its underlying mechanisms.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Atrial fibrillation is the most prevalent sustained cardiac arrhythmia, leading to substantial patient and healthcare burdens.
  • Current treatments focus on managing existing atrial fibrillation with anticoagulation or rate/rhythm control, but optimal strategies for reducing morbidity and mortality are still debated.

Purpose of the Study:

  • To explore the potential of angiotensin receptor blockers (ARBs) as a preventative strategy for atrial fibrillation.
  • To elucidate the multifaceted mechanisms through which ARBs may prevent atrial fibrillation.

Main Methods:

  • Review of existing literature on atrial fibrillation pathophysiology and ARB mechanisms of action.
  • Analysis of how ARBs influence atrial myocyte ion currents, refractoriness, and fibrosis.
  • Evaluation of ARB effects on cardiac structural remodeling (left atrial size, left ventricular hypertrophy) and neuro-hormonal modulation.

Main Results:

  • ARBs demonstrate a wide range of beneficial effects relevant to atrial fibrillation prevention.
  • These effects include modulating ion channel function, reducing atrial fibrosis, decreasing cardiac chamber size, and mitigating inflammation and hypertension.

Conclusions:

  • Angiotensin receptor blockers represent a promising therapeutic avenue for the prevention of atrial fibrillation.
  • Their pleiotropic effects offer a potential alternative strategy to reduce cardiovascular morbidity and mortality in at-risk populations.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...